This is a working overview of lyophilisation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
In addition to functioning as CoA, this compound can act as an acyl group carrier to form acetyl-CoA and other related compounds; this is a way to transport carbon atoms within the cell. CoA is also required in the formation of acyl carrier protein (ACP), which is required for fatty acid synthesis. Its synthesis also connects with other vitamins such as thiamin and folic acid.
Several potassium-containing reagents, so-called primary standards, have the advantage of being non-hygroscopic, in contrast the corresponding sodium salts. Thus, the oxidant potassium dichromate, the acid potassium hydrogen phthalate, and the reductant potassium ferrocyanide can be handled in air without gaining weight by hydration. Potassium salts are often produced from the sodium salts e.g., sodium chromate and sodium permanganate, which are more directly obtained from ores.
Neurotransmitter binds to the receptor The receptor undergoes a conformational change to allow G-protein complex binding GDP is exchanged with GTP upon G protein complex binding to the receptor The α-subunit of the G protein complex is bound to GTP and separates to bind with a target protein such as adenylate cyclase The binding to the target protein either increases or decreases the rate of second messenger (such as cyclic AMP) production GTPase hydrolyzes the α-subunit so that is bound to GDP and the α-subunit returns to the G protein complex inactive
=== Biosimilars === Much of Biocon's current market share includes biosimilars, licensed versions of existing "innovator" products. Biosimilars are eligible for manufacture and sale after the expiration of the original product's patent protection. These are produced under its subsidiary Biocon Biologics. In 2016, it became the first Indian company to launch a biosimilar insulin glargine pen in Japan. In 2017, USFDA approved Mylan-Biocon's biosimilar for the cancer drug Herceptin. In 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine. In 2022 a Biocon subsidiary, Biocon Biologics, bought the biosimilar assets of Viatris for $3.34 billion. In 2021, Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, the first interchangble biosimilar for diabetes in the United States. The same year, Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to the Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period. In December 2025, Biocon discontinued its production of the low-cost insulin glargine biosimilar Semglee (insulin glargine-yfgn), causing a significant shortage of basal insulins in the United States as demand moved to other options, in particular Sanofi's Lantus.
The Organisation for Economic Co-operation and Development (OECD; French: Organisation de coopération et de développement économiques, OCDE) is an intergovernmental organisation with 38 member countries. It was founded in 1961 to stimulate economic progress and world trade. The OECD is a forum whose member countries describe themselves as committed to democracy and the market economy, providing a platform for collective problem-solving, analysis, and coordination. In 2026, their collective population was 1.38 billion people with high levels of human development. As of 2026, OECD member countries collectively comprised 58.4% of global nominal GDP and 38.9% of global GDP at purchasing power parity. The OECD is an official United Nations observer. Member states have strong social security systems. The OECD is headquartered at the Château de la Muette in Paris, France. The OECD is funded by contributions from member countries and publishes annual reports on economic data as well as a variety of evaluations and rankings.
Sources: en.wikipedia.org
== Feeding == The mouth of the Hydra is surrounded by tentacles. When feeding, Hydra extend their body to maximum length and then slowly extend their tentacles. The tentacles of Hydra are extensible and can be four to five times the length of the body. To search for prey, Hydra extends its tentacles and slowly maneuvers them, waiting for contact. Upon contact with a prey, the stenoteles discharges neurotoxins; the desmonemes on the tentacle (nematocysts) also discharge threads that coil around the prey. Most of the tentacles join in the attack within 30 seconds. Within two minutes, the tentacles move the prey into the open mouth aperture. Within ten minutes, the prey is engulfed and digestion commences. A Hydra, with a column length of approximately 3–30 mm when extended and a width of about 1 mm, can stretch its body wall to digest prey more than twice its size. After 2–3 days, the indigestible remains will be discharged through the mouth aperture via contractions.The Hydra's mouth is not permanent: When the Hydra closes its mouth, the cells surrounding the open mouth fuse together. These joints are then broken when the Hydra feeds again.
However, at least one court case has resulted in a product being taken off the market. In December 2010, the United States Food and Drug Administration (FDA) issued a warning to consumers about such products stating, "The FDA has found many products marketed as dietary supplements for sexual enhancement during the past several years that can be harmful because they contain active ingredients in FDA-approved drugs or variations of these ingredients."
==== Singapore ==== Chick-fil-A opened a pop-up restaurant at Esplanade Mall for three days from June 26 through 28, 2024, being the first Asian country to host a Chick-fil-A pop-up. On October 17, 2024, Chick-fil-A officially announced it would be opening in Singapore in late 2025, making the first Asian country to open the brand, and would be investing US$75 million into its first restaurant in the country for 10 years. The restaurant opened on December 11, 2025.
=== Scottish === Daughters of Scotland - Incorporated in Ohio on October 3, 1899. Membership is open only to those of Scottish blood. Rituals had signs, oaths, and prayers. Grand Lodge dissolved in the early 1970s, though some local groups continued to meet afterwards. Order of Scottish Clans Sons of Scotland Benevolent Association - Founded 1876 in Toronto. Incorporated in Ontario in 1880, and on the federal level in 1937. Headquartered in Toronto, the association's lodges are called "Subordinate Camps", and the national structure is "Grand Camp", which meets in conventions triennially. Slogan "Lealty, Loyalty, Liberality". In the late 1970s, it still had an initiation ceremony and "affinity for fraternal ritualism", annual passwords, and regalia. In addition to insurance, it sponsors Scottish dancing and piping competitions, and parades in Scottish kilts. Membership is open to men and women of Scottish descent or their spouses. Five classes of membership - insured, central camp, juvenile, associate, and at large. Members are chosen by blackball. 1973 membership 12,887; 1979 membership 12,640 in 80 camps. 9,000 members in 1995. Charitable activities include Kidney Foundation of Canada and Alzheimer's disease organizations. Lost a third of its membership over the 1980s.
=== Types of rhinoplasty === In plastic surgical praxis, the term primary rhinoplasty denotes an initial (first-time) reconstructive, functional, or aesthetic corrective procedure. The term secondary rhinoplasty denotes the revision of a failed rhinoplasty, an occurrence in 5–20 per cent of rhinoplasty operations, hence a revision rhinoplasty. The corrections usual to secondary rhinoplasty include the cosmetic reshaping of the nose because of a functional breathing deficit from an over aggressive rhinoplasty, asymmetry, deviated or crooked nose, areas of collapses, hanging columella, pinched tip, scooped nose and more. Although most revision rhinoplasty procedures are "open approach", such a correction is more technically complicated, usually because the nasal support structures either were deformed or destroyed in the primary rhinoplasty; thus the surgeon must re-create the nasal support with cartilage grafts harvested either from the ear (auricular cartilage graft) or from the rib cage (costal cartilage graft). A functional rhinoplasty refers to a rhinoplasty performed to alleviate nasal obstruction, whereas a cosmetic rhinoplasty refers to a rhinoplasty performed for aesthetic reasons. Procedures performed as part of a functional rhinoplasty typically include septoplasty, inferior turbinate reduction, and spreader graft placement. Results Can be good if performed by an experienced practitioner. As in all plastic surgery procedures, there can be some unpredictability, and biologic systems can heal in different ways.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.